CyTOF Summit on Immuno-Oncology Playlist

→ Welcome and Introduction
Andrew Quong, PhD, Standard BioTools™
Jonathan Irish, PhD, Vanderbilt University

An introduction to our educational and thought-provoking program, in which you will hear about applications, experimental design and data analysis approaches being applied by innovative investigators from academia, biotech and pharma with a focus on immuno-oncology.

→ High-Content Cytometry Solutions for Investigation, Discovery and Therapeutic Development in Immuno-Oncology
Roberto Spada, PhD, Standard BioTools

A brief overview of the use of CyTOF® technology to date in immuno-oncology, as well as an introduction of the newest products offered by Standard BioTools that are particularly relevant for the immuno-oncology field.

→ Customization of the Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Pathsetter™ for Use in a Biotech Setting
Pedro Estrada, MS, 2seventy bio™

Estrada discusses the significance of studying the proteome of single cells as a critical part of understanding and advancing immunotherapy studies and how the ease of customizing ready-to-use Standard BioTools immune profiling panels and workflows has sped time-to-answer for 2seventy bio.

→ Simultaneous Quantification of Multiple Targets With Mass Cytometry to Support Biotherapeutic Drug Development
Chad Stevens, MS, Pfizer Worldwide Research & Development

Stevens introduces an approach for simultaneous analysis of multiple cell surface drug target receptors in diverse cell populations based on deep immunophenotyping of human whole blood samples. This technique is being used in biotherapeutic development to inform modeling and simulation teams on target feasibility and coverage requirements at Pfizer.

→ Connecting Cells to Patient Outcomes
Jonathan Irish, PhD, Vanderbilt University

Irish presents his latest work on glioblastoma, focusing on contrasting immune microenvironments seen in glioblastoma tumor types that can be detected on MRI. He discusses the use of CyTOF as a great technique for quantifying and characterizing all of the cells that are present in the tissue, including key navigation, T cell subtyping, activation and memory, checkpoint and life and death markers that allow measurement of what correlates with treatment responses or prognostic signatures.

→ An Unsupervised Learning Approach to Quantifying T Cell States From High-Plex Cytometry Data in Cancer Immunotherapy Clinical Trials
Dimitrios Sidiropoulos, PhD Candidate, Johns Hopkins School of Medicine

Cytometric studies surveying cell phenotypes often do not account for functional states of immune cells that occur along continuous phenotypic transitions. To overcome this limitation, Sidiropoulos explains how he and his team have applied single-cell trajectory inference and non-negative matrix factorization methods to CyTOF data to trace the dynamics of T cell states.

→ Cellular Microenvironments in Stem Cell Niche Contacting Glioblastoma
Rebecca Ihrie, PhD, Vanderbilt University

Ihrie outlines how CyTOF has been particularly useful in dissecting the complex mix of cell types present in glioblastoma by enabling cell classification and how Imaging Mass Cytometry™ supports an understanding of cell interactions in the tumor microenvironment and furthers insights into the connection of tumor contact status with prognosis.

→ Immune Correlates of GD2 CAR T Cell Expansion in Pediatric Osteosarcoma and Neuroblastoma Patients
Sneha Ramakrishna, MD, Center for Cancer Cell Therapy, Stanford University School of Medicine

Ramakrishna conducted a phase I trial (NCT02107963) to determine the feasibility of production and safety of administering escalating doses of GD2.Ox40.CD28.z chimeric antigen receptor T cells (GD2-CAR T) in children and young adults with neuroblastoma and osteosarcoma. She explains the robust GD2-CAR T expansion observed in half of the patients but limited persistence in all patients.

→ Panel Discussion
Moderator: Rebecca Ihrie, PhD, Vanderbilt University

Panel members come together to jointly answer questions from the audience on their research and use of CyTOF technology in immuno-oncology. They discuss how they have collected and analyzed comprehensive CyTOF data and converted their analyses into clinically relevant insights.